.jpg)
Nasdaq Nordic congratulates Zealand Pharma A/S on its dual listing on the Nasdaq Stock Market in New York. Zealand Pharma A/S is a Danish biotechnology company focused on the discovery, design and development of peptide-based medicines and is since 2010 listed on Nasdaq Copenhagen.
CEO of Zealand Pharma Britt Meelby Jensen said: ”To us it is an achievement and a major milestone that we today show Zealand to be an attractive player on the US biotech scene, the largest in the world. Our Nasdaq listing in New York will be a strong supplement to our primary listing on Nasdaq Copenhagen as it eases access to a large and unique group of investors in the US with highly specialized competencies.”
Adam Kostyál, SVP and Head of European listings at Nasdaq said: ”We congratulate Zealand Pharma on its listing on the Nasdaq market in New York, and hope a door to the US biotech investors has been opened. Biotech is one those sectors where American investors and analysts are highly specialized and it makes us proud to have been able to build a bridge to New York together with Zealand Pharma. We look forward to continue to support and partner with Zealand Pharma from both sides of the Atlantic.”
To celebrate the dual listing Zealand Pharma and CEO Britt Meelby Jensen will be opening the Nasdaq market on Thursday August 10 with the traditional NasdaqBell Ceremony from Times Square, New York.
Follow the Bell Ceremony live here: https://new.livestream.com/nasdaq/live
